Zobrazeno 1 - 10
of 1 416
pro vyhledávání: ''
Autor:
David A. Lynch, Stephen M. Humphries, Eszter K. Vladar, Connor D Balkissoon, Daniel M. Beswick, Jennifer L. Taylor-Cousar, Matthew Strand
Publikováno v:
Annals of the American Thoracic Society
Rationale Elexacaftor, tezacaftor, and ivacaftor (ETI) in triple combination improves pulmonary health for people with cystic fibrosis (PwCF). However, its impact on objective measures of sinus disease and health utility is unestablished. Objectives
Autor:
Laura Moran, Elisa H. Ignatius, Susan Swindells, Paolo Denti, Richard Hafner, Florian von Groote-Bidlingmaier, Eric L. Nuermberger, Naadira Vanker, Soyeon Kim, Andreas H. Diacon, Kathleen Donahue, Kelly E. Dooley, Susan L. Rosenkranz, Kamunkhwala Gausi, Xin Sun, Lubbe Wiesner
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:1327-1335
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but...
Autor:
Sarath Ranganathan, Barry Linnane, André Schultz, Graham L. Hall, Paul McNally, Yuliya V. Karpievitch, S. Stick, Daryl Butler
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:605-608
Autor:
Anna De Paris, Michele Montuori, Anna Marchesini, Riccardo Pini, Vittorio Palmieri, Irene Tassinari, Elisa Capretti, Adriana Gianno, Francesca Innocenti
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:365-368
Autor:
Rosemarie B. Dudenhofer, Pingsheng Wu, Margaret L. Salisbury, Wendi R. Mason, Timothy S. Blackwell, James E. Loyd, Guixiao Ding, Lisa Lancaster, Jonathan A. Kropski, James Del Greco, Susan Martin, Justin C. Hewlett
Publikováno v:
Annals of the American Thoracic Society. 18:1291-1297
Rationale: Human herpesviruses Epstein-Barr virus and cytomegalovirus are frequently detectable in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and could contribute to disease pat...
Autor:
Fernando Torres, Meagan Spychala, Ashley Pinckney, Paul M. Hassoun, Carla D’Aveta, Lynette Keyes-Elstein, David B. Badesch, Mark R. Nicolls, Holden Maecker, Beverly Welch, R. James White, Jerry A. Molitor, Robyn T. Domsic, Dinesh Khanna, Roham T. Zamanian, Lorinda Chung, Thomas A. Medsger, Ellen Goldmuntz, Andrew J. Sweatt
Publikováno v:
Am J Respir Crit Care Med
Rationale: Systemic sclerosis (SSc)–pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. Objectives: We investigated the safety and efficacy of B-cell depletion for
Autor:
Klaus Uwe Kirchgaessler, Toby M. Maher, Mark Atwood, Philip L. Molyneaux, Derek Weycker, Argyrios Tzouvelekis, Justin M. Oldham, Michael Kreuter, Joyce S. Lee
Publikováno v:
American journal of respiratory and critical care medicine, vol 204, iss 1
Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and interferon gamma-
Autor:
Nilay Shah, Xiaoxi Yao, Timothy M. Dempsey, Lindsey R. Sangaralingham, Stephanie Payne, Andrew H. Limper
Publikováno v:
Annals of the American Thoracic Society. 18:1121-1128
Rationale: In October 2014, the antifibrotic medications pirfenidone and nintedanib became the first medications approved by the U.S. Food and Drug Administration for use in patients with idiopathi...
Autor:
Pierre-Régis Burgel, Isabelle Durieu, Raphaël Chiron, Sophie Ramel, Isabelle Danner-Boucher, Anne Prevotat, Dominique Grenet, Christophe Marguet, Martine Reynaud-Gaubert, Julie Macey, Laurent Mely, Annlyse Fanton, Sébastien Quetant, Lydie Lemonnier, Jean-Louis Paillasseur, Jennifer Da Silva, Clémence Martin, Claire Andrejak, Arnaud Becourt, Julie Mounard, Claire Poulet, Cinthia Rames, Marie Talleux, Marie-Chantal Chevalier, Estelle Darviot, Marie Jouvenot, Caroline Marien, Audrey Paris, Cécile Pelatan, Christine Person, Pascaline Priou, Françoise Troussier, Thierry Urban, Marie-Laure Dalphin, Jean-Charles Dalphin, Alice Ladaurade, Didier Pernet, Bénédicte Richaud-Thiriez, Pauline Roux-Claude, Nathalia Blanc, Vincent Boisserie-Lacroix, Stephanie Bui, Cyrielle Collet, Stéphane Debelleix, Emmanuel Bergot, Jacques Brouard, Karine Campbell, Muriel Laurans, Virginie Ribault, Corinne Borderon, Marie-Christine Heraud, Guillaume Labbe, Sylvie Montcouquiol, Isabelle Petit, Marc Ruivard, Céline Delestrain, Benoit Douvry, Ralph Epaud, Bernard Maitre, Natascha Remus, Guillaume Beltramo, Anne Houzel, Frédéric Huet, Stéphanie Perez, Amale Boldron-Ghaddar, Manuela Scalbert, Rabah Bouzioukh, Charles Simon, Boubou Camara, Rébecca Hamidfar, Catherine Llerena, Isabelle Pin, Antoine Deschildre, Alice Gicquello, Olivier Le Rouzic, Clara Leroy, Nicolas Paris, Thierry Perez, Caroline Thumerelle, Dominique Turck, Nathalie Wizla, Magali Dupuy-Grasset, Jane Languepin, Alexandra Masson-Rouchaud, Céline Menetrey, Stéphane Durupt, Sophie L’Excellent, Raphaele Nove-Josserand, Camille Ohlmann, Phillipe Reix, Quitterie Reynaud, Marie-Christine Werck-Gallois, Mélissandre Baravalle, Bérangère Coltey, Nadine Desmazes-Dufeu, Jean-Christophe Dubus, Clarisse Gautier, Jean-Baptiste Rey, Nathalie Stremler, Davide Caimmi, Margot Devrait, Johan Moreau, Yves Billon, Aurore Blondé, Anne Guillaumot, Sébastien Kiefer, Laura Peretti, Aurélie Tatopoulos, Angélica Tiotiu, Myriam Benhamida, Tiphaine Bihouee, Emmanuel Eschapasse, Adrien Tissot, Marie Giannantonio, Sylvie Leroy, Carole Piccini-Bailly, Johana Pradelli, Jonathan Messika, Véronique Boussaud, Nicolas Carlier, Isabelle Honoré, Dominique Hubert, Reem Kanaan, Céline Bailly-Botuha, Frédérique Chedevergne, Jacques De Blic, Christophe Delacourt, David Drummond, Brigitte Fauroux, Chantal Karila, Muriel Le Bourgeois, Isabelle Sermet, Bertrand Delaisi, Michèle Gerardin, Veronique Houdouin, Laurence Leclainche, Guillaume Aubertin, Laura Berdah, Annick Clement, Harriet Corvol, Nadia Nathan, Blandine Prevost, Nicolas Richard, Aline Tamalet, Jessica Taytard, Guillaume Thouvenin, Barbara Tourniaire, Michel Abely, Katia Bessaci-Kabouya, Sandra Dury, Bruno Ravoninjatovo, Alain Dabadie, Michel Dagorne, Eric Deneuville, Marie Jamin, Mélanie Ribault, Clémentine Vigier, Chantal Belleguic, Graziella Brinchault, Benoit Desrues, Audrey Barzic, Anne Dirou-Prigent, Jean Le Bihan, Krista Revert, Thomas Ropars, Laure Couderc, Stéphane Dominique, Hélène Morisse-Pradier, Stéphanie Pramil, Luc Thiberville, Nathalie Allou, Laurent Enaud, Elsa Gachelin, Eric Huchot, Annabelle Payet, Caroline Perisson, Saguiraly Piyaraly, Sophie Valois, Audrey Herzog, Romain Kessler, Michele Porzio, Laurence Weiss, Laurence Beaumont, Olivier Brugiere, Sylvie Colin, de Verdiere, Elise Cuquemelle, Sandra De Miranda, Adbdul Monem Hamid, François Parquin, Clément Picard, Antoine Roux, Charlotte Roy, François Bremont, Alain Didier, Marion Dupuis, Guillaume Faviez, Géraldine Labouret, Marie Mittaine, Marlène Murris-Espin, Léa Roditis, Laure Cosson, Patrice Diot, Thomas Flament, Charlotte Giraut, Julie Mankikian, Baptiste Arnouat, Gaétane Mousset, Véronique Storni, Philippe Vigneron, Emmanuelle Coirier-Duet, Asma Gabsi
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
American Journal of Respiratory and Critical Care Medicine, 2021, 204 (1), pp.64-73. ⟨10.1164/rccm.202011-4153OC⟩
American Journal of Respiratory and Critical Care Medicine, 2021, 204 (1), pp.64-73. ⟨10.1164/rccm.202011-4153OC⟩
International audience; Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evalua
Autor:
Edward F. McKone, Chenghao Chu, Claire E. Wainwright, Neil Ahluwalia, Samuel M. Moskowitz, Paul McNally, Edith T. Zemanick, Ronald L. Gibson, Jane Davies, Fengjuan Xuan, Steven M. Rowe, Tanya G. Weinstock, Bonnie W. Ramsey, Elizabeth Tullis, Susanna A McColley, David Waltz, S. Tian, Thang Ho, Jonathan H. Rayment, Sabrina Noel, Marcus A. Mall, Jennifer L. Taylor-Cousar
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 203:1522-1532
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic fibrosis trans...